Navigation Links
UF oncologists fight leukemia with two-pronged therapy, clinical trials planned
Date:6/3/2010

A new therapy mounts a double-barreled attack on leukemia, targeting not just the cancer cells but also the environment in which those cells live and grow, University of Florida researchers report.

Like striking an enemy camp directly as well as cutting off its source of food and other resources, the agent, called Oxi4503, poisons leukemia cells and destroys the blood vessels that supply them with oxygen and nutrients.

Use of the treatment in mouse models of acute myelogenous leukemia, or AML, is described online and in an upcoming print issue of the journal Blood. The researchers plan human tests of the drug at Shands at UF later this year.

"We've identified a new tool to dissect out the specifics of the relationship between leukemia cells and the blood vessels that supply them," said Christopher Cogle, M.D., the UF College of Medicine oncologist who is senior author of the paper and a member of the UF Shands Cancer Center. "What we are offering is a brand new treatment by a very different mechanism to people who desperately need something new."

Each year, more than 120,000 people in the United States are diagnosed with a blood cancer, and about 80 percent of them die of the disease because there are no effective treatments, according to the National Cancer Institute. Some AMLs return after initially successful chemotherapy, while others do not respond at all. In addition, chemotherapy is too toxic for some elderly people, so they need an alternative.

Many treatments and studies focus on killing cancer cells, but very few target the microenvironment in which those cells grow. That means paying attention to blood vessels, bone marrow, growth factors and cell-to-cell interaction and binding.

Existing therapies that destroy blood vessels do so by targeting a growth factor called VEGF-A, but they are not effective long term at eliminating leukemia. To try to find a strategy that attacked multiple targets
'/>"/>

Contact: Czerne M. Reid
czerne@ufl.edu
352-273-5814
University of Florida
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UAB oncologists: HPV vaccine protects from cancer recurrence
2. Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test
3. Blood-thinning copycat enters malaria fight
4. Bodys own proteins may lead the way in global fight against tuberculosis
5. Symposium spotlights new paradigms in genomics, celebrates AIDS-fighting drug at 25 years
6. Fighting fungal infections with bacteria
7. The fight against uterine fibroid tumors
8. UT Southwestern researchers identify key molecular step to fighting off viruses
9. New evidence that green tea may help fight glaucoma and other eye diseases
10. Carbon nanotubes boost cancer-fighting cells
11. Researchers harness the power of plants to fight hemophilia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Mass. Researchers at the University of Massachusetts Medical School ... is implicated in 20 percent of inherited cases of amyotrophic ... part in sporadic forms of the disease. Discovery of this ... of Nature Neuroscience . While the SOD1 gene ...
... American Academy of Ophthalmology (AAO) - Middle East-Africa ... report on beta carotene,s ability to improve ... The AAO-MEACO meetingthe world,s largest, most comprehensive ophthalmic ... at McCormick Place, Chicago. 9-cis Beta-Carotene Mat ...
... often compared to a book. However, it is not so much ... like a cookbook. The cell reads only those recipes which are ... ,reading, in the book of the cell means creating RNA copies ... The cell uses highly complex, sophisticated regulatory mechanisms to make ...
Cached Biology News:UMMS researchers identify protein associated with sporadic ALS 2UMMS researchers identify protein associated with sporadic ALS 3A mystery solved: How genes are selectively silenced 2
(Date:4/30/2015)... Clinovo Staffing Solutions will ... held in Orlando, FL on May 17-20th, 2015. ... Leslie Kolman, Manager of Staffing Solutions, will present Clinovo’s ... Booth #17. , “We are excited to be ... Says Trisha Heredia, Senior Director of Staffing Solutions at ...
(Date:4/29/2015)... USA (PRWEB) April 29, 2015 ... sensing, and imaging on the East Coast, reaffirmed its ... managers, researchers, applications developers, and industry suppliers to meet ... imaging for multiple applications. , The event included 55 ... commercial and scientific sensing and imaging -- and an ...
(Date:4/29/2015)... 2015 Cambrex Corporation (NYSE: CBM ) announced ... Friday, May 1, 2015 before the market opens. , ... host a conference call to discuss the financial results. First ... , Friday, May 1, 2015 at 8:30 a.m. Eastern ... U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... Gene therapy can clip out genetic material linked to ... human cardiac cells, according to a study led by researchers ... at Mount Sinai. The study is published in the April ... small random, changes in the genetic code making up genes, ... patients with heart failure,” says Roger J. Hajjar, MD, Director ...
Breaking Biology Technology:Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4Gene Therapy Clips Out Heart Failure Causing Gene Mutations 2Gene Therapy Clips Out Heart Failure Causing Gene Mutations 3Gene Therapy Clips Out Heart Failure Causing Gene Mutations 4
... (Nasdaq:,CEPH) today announced that the U.S. Food and ... Drug Application (sNDA) for,FENTORA(R) (fentanyl buccal tablet) [C-II] ... with chronic pain. In,addition, the FDA notified the ... on May 6, 2008, to consider this application., ...
... AMDL, Inc. (Amex:,ADL), headquartered in Tustin, ... China, through its wholly owned subsidiary Jade,Pharmaceutical ... together,with Jade, engages in the development, manufacture ... diagnostic products. It today,announced that more than ...
... Jan. 25 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ... Administration,(FDA) has approved the company,s most current lot ... first lot to be released with extended,expiration dating. ... thrombolytic or clot-dissolving agent indicated,for the treatment of ...
Cached Biology Technology:Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application 2Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application 3AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000 2ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating 2ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating 3
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
... converts Cap 0 (or Cap 0-like) RNA ... structure has been shown to increase in ... This improvement is seen in Cap 0 ... System as well as those Cap 0 ...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: